Dewpoint Therapeutics
As Director of External Innovation, Michael helps solve some of the most pressing challenges in the biomolecular condensate field by working closely with the R&D and business development teams to source and evaluate emerging technological and therapeutic assets of strategic interest, as well as efficiently manage the world-class scientific advisory board, and foster collaborations with a variety of current and future partners.
This person is not in any teams
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.